# Joachim G.J.V. Aerts

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joachim-g-j-v-aerts/

## Facts

| Field | Value |
| --- | --- |
| Citations | 31,526 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 71 |
| i10-index | 264 |
| Last Known Institution | VIB-UGent Center for Inflammation Research |
| OpenAlex ID | https://openalex.org/A5012937808 |
| ORCID iD | https://orcid.org/0000-0001-6662-2951 |
| Works | 688 |

## Researcher papers

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021](https://scholariq.org/papers/estimated-global-proportions-of-individuals-with-persistent-fatigue-cognitive/)
- [The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes](https://scholariq.org/papers/the-pd-1-pd-l1-checkpoint-restrains-t-cell-immunity-in-tumor-draining-lymph/)
- [Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus/)
- [IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain](https://scholariq.org/papers/impower150-final-exploratory-analyses-for-atezolizumab-plus-bevacizumab-and/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [VIB-UGent Center for Inflammation Research](https://scholariq.org/institutions/vib-ugent-center-for-inflammation-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.